7639 Background: Erlotinib is an orally available selective EGFR tyrosine-kinase inhibitor.
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …

Objective To observe the efficacy and the adverse effects of erlotinib in the treatment for
advanced non-small cell lung cancer (NSCLC) in Chinese patients. Methods From …

The activity of erlotinib after gefitinib failure in non-small cell lung cancer patients with all
four favorable clinical factors including female, never smoker, Asian, and adenocarcinoma …

Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Purpose Erlotinib is the first epidermal growth factor receptor–tyrosine kinase inhibitor
shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a critical
member of systemic therapy for advanced non-small-cell lung cancer (NSCLC). Erlotinib is …

Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …